Sargramostim (recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF)) has been used clinically for nearly 30 years and has been used as a treatment adjunct for other inflammatory diseases of the bowel, such as Crohn’s disease or ulcerative colitis. The gene discussed is CSF2; the disease is Crohn disease.